March 12, 2018 / 8:12 PM / in 8 months

BRIEF-Advaxis Reports Q1 Loss Per Share $0.49

March 12 (Reuters) - Advaxis Inc:

* ADVAXIS REPORTS FISCAL 2018 FIRST QUARTER FINANCIAL RESULTS AND ANNOUNCES CLINICAL HOLD IN AXALIMOGENE FILOLISBAC PHASE 1/2 COMBINATION STUDY WITH ASTRAZENECA’S IMFINZI® (DURVALUMAB)

* Q1 LOSS PER SHARE $0.49

* Q1 EARNINGS PER SHARE VIEW $-0.55 — THOMSON REUTERS I/B/E/S

* ADVAXIS - FDA NOTIFIED IND FOR PHASE 1/2 COMBO STUDY OF AXALIMOGENE FILOLISBAC WITH IMFINZI FOR HPV-ASSOCIATED CANCERS WAS PLACED ON CLINICAL HOLD

* CLINICAL HOLD PERTAINS TO RECENT SUBMISSION OF SAFETY REPORT TO FDA REGARDING GRADE 5 SERIOUS ADVERSE EVENT ON FEBRUARY 27

* ADVAXIS - ENROLLMENT AND DOSING IN ALL OTHER ADVAXIS CLINICAL PROGRAMS ARE UNAFFECTED AT THIS TIME

* ADVAXIS - “WE ARE CONFIDENT IN SAFETY AND EFFICACY PROFILE OF AXALIMOGENE FILOLISBAC, TO DATE” Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below